AJP - Heart Add DOIs to your references at manuscript stage!
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Am J Physiol Heart Circ Physiol 295: H816-H825, 2008. First published June 20, 2008; doi:10.1152/ajpheart.01348.2007
0363-6135/08 $8.00
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
295/2/H816    most recent
01348.2007v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Dayal, S.
Right arrow Articles by Lentz, S. R.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dayal, S.
Right arrow Articles by Lentz, S. R.

Tissue-specific downregulation of dimethylarginine dimethylaminohydrolase in hyperhomocysteinemia

Sanjana Dayal,1 Roman N. Rodionov,1 Erland Arning,3 Teodoro Bottiglieri,3 Masumi Kimoto,4 Daryl J. Murry,5 John P. Cooke,6 Frank M. Faraci,1,2 and Steven R. Lentz1,7

Departments of 1Internal Medicine and 2Pharmacology, University of Iowa Carver College of Medicine, Iowa City, Iowa; 3Baylor Institute of Metabolic Disease, Dallas, Texas; 4Department of Nutritional Science, Okayama Prefectural University, Okayama, Japan; 5University of Iowa College of Pharmacy, Iowa City, Iowa; 6Stanford University, Palo Alto, California; and 7Veterans Affairs Medical Center, Iowa City, Iowa

Submitted 17 November 2007 ; accepted in final form 17 June 2008

Asymmetric dimethylarginine (ADMA), an endogenous inhibitor of nitric oxide (NO) synthase, has been proposed to be a mediator of vascular dysfunction during hyperhomocysteinemia. Levels of ADMA are regulated by dimethylarginine dimethylaminohydrolase (DDAH). Using both in vitro and in vivo approaches, we tested the hypothesis that hyperhomocysteinemia causes downregulation of the two genes encoding DDAH (Ddah1 and Ddah2). In the MS-1 murine endothelial cell line, the addition of homocysteine decreased NO production but did not elevate ADMA or alter levels of Ddah1 or Ddah2 mRNA. Mice heterozygous for cystathionine β-synthase (Cbs) and their wild-type littermates were fed either a control diet or a high-methionine/low-folate (HM/LF) diet to produce varying degrees of hyperhomocysteinemia. Maximal relaxation of the carotid artery to the endothelium-dependent dilator acetylcholine was decreased by ~50% in Cbs+/– mice fed the HM/LF diet compared with Cbs+/+ mice fed the control diet (P < 0.001). Compared with control mice, hyperhomocysteinemic mice had lower levels of Ddah1 mRNA in the liver (P < 0.001) and lower levels of Ddah2 mRNA in the liver, lung, and kidney (P < 0.05). Downregulation of DDAH expression in hyperhomocysteinemic mice did not result in an increase in plasma ADMA, possibly due to a large decrease in hepatic methylation capacity (S-adenosylmethionine-to-S-adenosylhomocysteine ratio). Our findings demonstrate that hyperhomocysteinemia causes tissue-specific decreases in DDAH expression without altering plasma ADMA levels in mice with endothelial dysfunction.

asymmetric dimethylarginine; endothelium; homocysteine; vascular function



Address for reprint requests and other correspondence: S. R. Lentz, Dept. of Internal Medicine, Univ. of Iowa, C32 GH, Iowa City, IA 52242 (e-mail: steven-lentz{at}uiowa.edu)







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online
Copyright © 2008 by the American Physiological Society.